Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.47 USD
Change Today -0.04 / -2.65%
Volume 111.9K
As of 10:35 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

gtx inc (GTXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/22/15 - $1.59
52 Week Low
10/14/14 - $0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GTX INC (GTXI)

gtx inc (GTXI) Related Bloomberg News

View More Bloomberg News

gtx inc (GTXI) Related Businessweek News

No Related Businessweek News Found

gtx inc (GTXI) Details

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of cancer and other serious medical conditions. Its lead product candidate, enobosarm (GTx-024), is in Phase 2 clinical trials for the treatment of women with advanced AR positive triple-negative breast cancer, and treatment of women with ER positive and AR positive advanced breast cancer. The company also develops Capesaris, an oral nonsteroidal estrogen receptor alpha agonist that is in Phase 2 clinical trial for secondary hormonal therapy in men with metastatic or nonmetastatic castration resistant prostate cancer. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

27 Employees
Last Reported Date: 05/11/15
Founded in 1997

gtx inc (GTXI) Top Compensated Officers

Co-founder, Chief Executive Officer and Direc...
Total Annual Compensation: $393.3K
Principal Financial & Accounting Officer, Sen...
Total Annual Compensation: $288.4K
Chief Legal Officer, Vice President, General ...
Total Annual Compensation: $545.4K
Compensation as of Fiscal Year 2014.

gtx inc (GTXI) Key Developments

GTx Regains Compliance With NASDAQ Bid Price Requirement

GTx, Inc. announced that it has received written communication from the NASDAQ Listing Qualifications Panel that the Company has regained compliance with the minimum bid price requirement under the NASDAQ Listing Rules as a result of the closing bid price of GTx’s common stock having been at or above the minimum requirement of $1.00 per share for a minimum of ten consecutive trading days. As a result, shares of GTx will continue to trade on the NASDAQ Capital Market and the matter related to GTx’s non-compliance with the minimum bid price requirement is now closed. In October 2014, the Company received correspondence from NASDAQ, requesting the Company to submit a plan to regain compliance with the minimum bid price requirement. In March 2015, the Company transferred its listing from the NASDAQ Global Market to the NASDAQ Capital Market. On April 1, 2015, the Company was afforded an additional 180-day grace period, through September 28, 2015, to comply with the minimum bid price requirement.

GTX Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM

GTX Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Robert James Wills, Executive Chairman and Chairman of Scientific & Development Committee.

GTX Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Plans to Initiate Two Open-Label Phase 2 Clinical Trials of Enobosarm in Breast Cancer

GTX Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of USD 5,059,000 compared to USD 8,989,000 a year ago. Net loss was USD 2,384,000 compared to USD 8,987,000 a year ago. Basic and diluted loss per share was USD 0.02 compared to USD 0.14 a year ago. In June 2015, the company plans to commence enrollment in an open-label, proof-of-concept Phase 2 clinical trial of enobosarm in patients with advanced AR+ TNBC. The study will enroll up to 55 patients with the primary efficacy objective defined as clinical benefit at 16 weeks. Soon thereafter, in the third quarter of 2015, the company plans to initiate enrollment in an open-label Phase 2 clinical trial of enobosarm in patients with ER+/AR+ advanced breast cancer. The study will enroll up to 118 patients with the primary efficacy objective defined as clinical benefit at 24 weeks. The company has completed enrollment of its open-label Phase 2 study of GTx-758 in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC). Both the 125 mg and 250 mg doses have demonstrated dose dependent increases in serum hormone binding globulin (SHBG), reductions in free testosterone and reductions in prostate specific antigen (PSA), confirming the mechanism of action of the compound.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GTXI:US $1.47 USD -0.04

GTXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GTXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation GTXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GTX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at